Stocks and Investing Stocks and Investing
Wed, September 19, 2018
Tue, September 18, 2018
Mon, September 17, 2018
Fri, September 14, 2018
Thu, September 13, 2018
Wed, September 12, 2018
Tue, September 11, 2018
Mon, September 10, 2018
Fri, September 7, 2018

Vamil Divan Downgraded (TEVA) to Hold and Decreased Target to $23 on, Sep 7th, 2018


Published on 2024-10-26 08:33:51 - WOPRAI
  Print publication without navigation


Vamil Divan of Credit Suisse, Downgraded "Teva Pharmaceutical Industries Limited" (TEVA) to Hold and Decreased Target from $25 to $23 on, Sep 7th, 2018.

Vamil has made no other calls on TEVA in the last 4 months.



There are 5 other peers that have a rating on TEVA. Out of the 5 peers that are also analyzing TEVA, 4 agree with Vamil's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Douglas Tsao of "Barclays" Maintained at Hold with Increased Target to $23 on, Monday, August 6th, 2018
  • David Risinger of "Morgan Stanley" Maintained at Hold with Increased Target to $20 on, Friday, August 3rd, 2018
  • Louise Chen of "Cantor Fitzgerald" Maintained at Hold with Increased Target to $25 on, Monday, July 16th, 2018
  • Jacob Hughes of "Wells Fargo" Upgraded from Sell to Hold on, Monday, June 18th, 2018


This is the rating of the analyst that currently disagrees with Vamil


  • Liav Abraham of "Citigroup" Maintained at Strong Buy with Increased Target to $25 on, Thursday, May 31st, 2018